Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Posted on: Wednesday, 28 January 2009, 15:30 CST
Investors and other interested parties may call 866-543-6405 (domestic) or 617-213-8897 (international) and enter passcode 10990222. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until
About Endo
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals Inc.
Source: PR Newswire
Related Articles
- Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
- OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
- Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis
- FDA Approves 10 MG ARICEPT(R) (Donepezil HCl Tablets) for Treatment of Severe Alzheimer's Disease
- U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
- Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for Treatment of Severe Ankylosing Spondylitis
- Colorado Becomes an International Center for Non-Fusion Treatment of Severe Spine Degeneration
- FDA Accepts Eisai's sNDA Application for ARICEPT(R) in the Treatment of Severe Alzheimer's Disease
- Eisai Submits Application to FDA for ARICEPT(R) for Treatment of Severe Alzheimer's Disease
- HUMIRA(R) (Adalimumab) Approved in Europe for the Treatment of Psoriatic Arthritis and As a First-Line Treatment of Severe Rheumatoid Arthritis
 |
 |
User Comments (0)
RSS Feeds